BL 11282

Drug Profile

BL 11282

Latest Information Update: 22 Jan 2003

Price : $50

At a glance

  • Originator Eli Lilly; Nonindustrial source
  • Developer Nonindustrial source
  • Class Imidazoles
  • Mechanism of Action Gastric inhibitory polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 07 May 2001 Preclinical development for Diabetes mellitus in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top